301 related articles for article (PubMed ID: 19279561)
1. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Ho MK; Mwenifumbo JC; Al Koudsi N; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2009 Jun; 85(6):635-43. PubMed ID: 19279561
[TBL] [Abstract][Full Text] [Related]
2. Utility and relationships of biomarkers of smoking in African-American light smokers.
Ho MK; Faseru B; Choi WS; Nollen NL; Mayo MS; Thomas JL; Okuyemi KS; Ahluwalia JS; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3426-34. PubMed ID: 19959692
[TBL] [Abstract][Full Text] [Related]
3. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
4. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
5. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.
Lea RA; Dickson S; Benowitz NL
J Anal Toxicol; 2006; 30(6):386-9. PubMed ID: 16872570
[TBL] [Abstract][Full Text] [Related]
6. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Mwenifumbo JC; Al Koudsi N; Ho MK; Zhou Q; Hoffmann EB; Sellers EM; Tyndale RF
Hum Mutat; 2008 May; 29(5):679-88. PubMed ID: 18360915
[TBL] [Abstract][Full Text] [Related]
7. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
Trials; 2011 Jan; 12():22. PubMed ID: 21266057
[TBL] [Abstract][Full Text] [Related]
8. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):23-34. PubMed ID: 17206525
[TBL] [Abstract][Full Text] [Related]
9. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of nicotine and its metabolites I. Model development.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):5-21. PubMed ID: 17206524
[TBL] [Abstract][Full Text] [Related]
11. Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.
Nagano T; Shimizu M; Kiyotani K; Kamataki T; Takano R; Murayama N; Shono F; Yamazaki H
Int J Environ Res Public Health; 2010 Jul; 7(7):2953-64. PubMed ID: 20717551
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.
Yuan JM; Nelson HH; Butler LM; Carmella SG; Wang R; Kuriger-Laber JK; Adams-Haduch J; Hecht SS; Gao YT; Murphy SE
Int J Cancer; 2016 May; 138(9):2161-71. PubMed ID: 26662855
[TBL] [Abstract][Full Text] [Related]
13. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
[TBL] [Abstract][Full Text] [Related]
14. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.
Swan GE; Lessov-Schlaggar CN; Bergen AW; He Y; Tyndale RF; Benowitz NL
Pharmacogenet Genomics; 2009 May; 19(5):388-98. PubMed ID: 19300303
[TBL] [Abstract][Full Text] [Related]
15. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.
Mwenifumbo JC; Sellers EM; Tyndale RF
Drug Alcohol Depend; 2007 Jun; 89(1):24-33. PubMed ID: 17161559
[TBL] [Abstract][Full Text] [Related]
16. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
Williams JM; Gandhi KK; Benowitz NL
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2582-9. PubMed ID: 20719908
[TBL] [Abstract][Full Text] [Related]
17. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
18. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
19. Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.
Piliguian M; Zhu AZ; Zhou Q; Benowitz NL; Ahluwalia JS; Sanderson Cox L; Tyndale RF
Pharmacogenet Genomics; 2014 Feb; 24(2):118-28. PubMed ID: 24305170
[TBL] [Abstract][Full Text] [Related]
20. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.
Zhu AZ; Renner CC; Hatsukami DK; Swan GE; Lerman C; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):708-18. PubMed ID: 23371292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
